Living Cell Technologies (LVCLF) Price & Analysis

Compare

2 Followers

LVCLF Stock Chart & Stats

$0.01

>-$0.01(-68.75%)

At close: Dec 30 4:00 PM EST

$0.01

>-$0.01(-68.75%)

Day’s Range― - ―

52-Week Range― - ―

Previous CloseN/A

Volume10.00K

Average Volume (3M)N/A

Market Cap

$19.28M

Enterprise Value$22.67M

Total Cash (Recent Filing)$1.88M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta3.62

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding1,712,938,400

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)3.79

Price to Sales (P/S)0.00

P/FCF Ratio-10.74

Enterprise Value/Market Cap1.18

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-11.10

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

No Debt / Low Financial LeverageZero reported debt materially reduces fixed interest obligations and insolvency risk for a pre-revenue biotech. This preserves strategic optionality to time clinical programs, negotiate partnerships, or raise equity without servicing debt, improving financial flexibility over the next 2–6 months.

Narrowing Net LossesA clear reduction in net losses signals improving operating efficiency or lower cash burn rate, which is a durable sign management is prioritizing runway and program sequencing. Sustained narrowing reduces reliance on immediate funding and lowers dilution risk if the trend continues.

Focused Regenerative-medicine PlatformA concentrated business model in encapsulated cell therapies for neurology and metabolic disorders aligns with structural demand for regenerative treatments. Specialized technology and long clinical horizons create high entry barriers and potential durable competitive advantage if clinical progress continues.

Bears Say

Effectively No RevenueSustained absence of meaningful revenue means the company cannot self-fund development or commercial activities, increasing dependency on external capital. Over 2–6 months this elevates execution risk, potential program delays, and the likelihood of dilutive financings to sustain operations.

Persistent Negative Cash FlowChronic negative operating and free cash flow indicate ongoing cash burn and lack of internal financing capacity. This structural cash shortfall pressures liquidity, shortens runway absent funding, and constrains investment in trials or commercialization, raising long-term execution risk.

Equity Erosion And Falling AssetsDeclining shareholders' equity and shrinking asset base weaken the balance sheet cushion, reducing negotiating leverage with partners and lenders. Over months this impairs resilience to setbacks, increases cost of capital, and may force unfavorable financing or program cuts if trends persist.

Living Cell Technologies News

Algorae Pharmaceuticals Issues 42 Million Performance Rights Under Incentive Scheme

Living Cell Technologies ( ($AU:1AI) ) has provided an update. Algorae Pharmaceuticals has issued 42,000,000 unquoted performance rights...

2d ago

Algorae Director Boosts Indirect Stake Through Option Exercise

An announcement from Living Cell Technologies ( ($AU:1AI) ) is now available. Algorae Pharmaceuticals has disclosed a change...

2d ago

Algorae Pharmaceuticals Issues New Shares Under Cleansing Notice

Living Cell Technologies ( ($AU:1AI) ) just unveiled an announcement. Algorae Pharmaceuticals has issued new fully paid ordinary...

2d ago

Algorae Pharmaceuticals Seeks ASX Quotation for 5.06 Million New Shares

Living Cell Technologies ( ($AU:1AI) ) has issued an announcement. Algorae Pharmaceuticals Limited has applied to the ASX...

2d ago

Algorae Pharmaceuticals Issues New Shares and Confirms Regulatory Compliance

The latest announcement is out from Living Cell Technologies ( ($AU:1AI) ). Algorae Pharmaceuticals has issued new fully...

8d ago

Algorae Pharmaceuticals Seeks ASX Quotation for 7.4 Million New Shares

An update from Living Cell Technologies ( ($AU:1AI) ) is now available. Algorae Pharmaceuticals Limited has applied to...

8d ago

Algorae Pharmaceuticals Files Half-Year Report and Highlights Dual AI and Commercial Focus

Living Cell Technologies ( ($AU:1AI) ) has provided an update. Algorae Pharmaceuticals has released its half-year report for...

9d ago

Algorae expands ANZ generics portfolio with Cadila cardiovascular and metabolic deal

Living Cell Technologies ( ($AU:1AI) ) has shared an update. Algorae Pharmaceuticals has signed a definitive licence and...

27d ago

Algorae Issues Confidential Non-Deal Investor Presentation with Strong Risk Disclaimers

The latest announcement is out from Living Cell Technologies ( ($AU:1AI) ). Algorae Pharmaceuticals has released a February...

1M ago

Algorae Pharmaceuticals Seeks ASX Quotation for 47,745 New Shares

Living Cell Technologies ( ($AU:1AI) ) just unveiled an announcement. Algorae Pharmaceuticals Limited has applied to the ASX...

1M ago

LVCLF FAQ

What was Living Cell Technologies Ltd.’s price range in the past 12 months?

Currently, no data Available

What is Living Cell Technologies Ltd.’s market cap?

Living Cell Technologies Ltd.’s market cap is $19.28M.

When is Living Cell Technologies Ltd.’s upcoming earnings report date?

Living Cell Technologies Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 179 days.

How were Living Cell Technologies Ltd.’s earnings last quarter?

Living Cell Technologies Ltd. released its earnings results on Mar 04, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.

Is Living Cell Technologies Ltd. overvalued?

According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Living Cell Technologies Ltd. pay dividends?

Living Cell Technologies Ltd. does not currently pay dividends.

What is Living Cell Technologies Ltd.’s EPS estimate?

Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Living Cell Technologies Ltd. have?

Living Cell Technologies Ltd. has 1,712,938,400 shares outstanding.

What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?

Living Cell Technologies Ltd. reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?

Currently, no hedge funds are holding shares in LVCLF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Living Cell Technologies Stock Smart Score

Neutral

Blogger Sentiment

Bullish

LVCLF Sentiment 100%
Sector Average ―

News Sentiment

Neutral

Bullish news 50%
Bearish news 50%

Fundamentals

Return on Equity

-30.33%

Trailing 12-Months

Asset Growth

-26.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Living Cell Technologies Ltd.

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.